Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022;29:1–7. https://doi.org/10.1080/13506129.2021.2002841.

Article  CAS  PubMed  Google Scholar 

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346–52. https://doi.org/10.1182/blood-2011-01-330738.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33:3741–9. https://doi.org/10.1200/JCO.2015.62.4015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gertz MA, Schonland S. Stem cell mobilization and autologous transplant for immunoglobulin light-chain amyloidosis. Hematol Oncol Clin North Am. 2020;34:1133–44. https://doi.org/10.1016/j.hoc.2020.07.007.

Article  PubMed  PubMed Central  Google Scholar 

Gutierrez-Garcia G, Cibeira MT, Rovira M, Fernandez de Larrea C, Tovar N, Rodriguez-Lobato LG, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019;54:1295–303. https://doi.org/10.1038/s41409-019-0447-y.

Article  CAS  PubMed  Google Scholar 

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–93. https://doi.org/10.1056/NEJMoa070484.

Article  CAS  PubMed  Google Scholar 

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, et al. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 2019;187:642–52. https://doi.org/10.1111/bjh.16143.

Article  CAS  PubMed  Google Scholar 

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93. https://doi.org/10.7326/0003-4819-140-2-200401200-00008.

Article  CAS  PubMed  Google Scholar 

Tandon N, Muchtar E, Sidana S, Dispenzieri A, Lacy MQ, Dingli D, et al. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplant. 2017;52:1126–32. https://doi.org/10.1038/bmt.2017.68.

Article  CAS  PubMed  Google Scholar 

Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood. 2012;120:4445–6. https://doi.org/10.1182/blood-2012-09-457341.

Article  CAS  PubMed  Google Scholar 

Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48:557–61. https://doi.org/10.1038/bmt.2012.170.

Article  CAS  PubMed  Google Scholar 

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51:2181–7. https://doi.org/10.3109/10428194.2010.524329.

Article  PubMed  Google Scholar 

Dingli D, Tan TS, Kumar SK, Buadi FK, Dispenzieri A, Hayman SR, et al. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology. 2010;74:913–8. https://doi.org/10.1212/WNL.0b013e3181d55f4d.

Article  CAS  PubMed  Google Scholar 

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58. https://doi.org/10.1056/NEJMoa2028631.

Article  CAS  PubMed  Google Scholar 

Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031–7. https://doi.org/10.1200/JCO.2009.23.8220.

Article  CAS  PubMed  Google Scholar 

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271–80. https://doi.org/10.1182/blood.2019000834.

Article  CAS  PubMed  Google Scholar 

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–95. https://doi.org/10.1200/JCO.2011.38.5724.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–7. https://doi.org/10.1182/blood-2012-12-473066.

Article  CAS  PubMed  Google Scholar 

Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787–9. https://doi.org/10.1016/S0140-6736(03)13396-X.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2016;31:1284–9. https://doi.org/10.1093/ndt/gfv328.

Article  CAS  PubMed  Google Scholar 

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, et al. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. Br J Haematol. 2019;186:460–70. https://doi.org/10.1111/bjh.15955.

Article  CAS  PubMed  Google Scholar 

Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine. 2003;82:291–8. https://doi.org/10.1097/01.md.0000091183.93122.c7.

Article  PubMed  Google Scholar 

Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–7. https://doi.org/10.1200/JCO.2004.03.029.

Article  CAS  PubMed  Google Scholar 

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–5. https://doi.org/10.1182/blood-2015-01-620302.

Article  CAS  PubMed  Google Scholar 

Muchtar E, Kumar SK, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood. 2019;133:763–6. https://doi.org/10.1182/blood-2018-10-875252.

Article  CAS  PubMed  Google Scholar